Insperity, Inc. (NSP) SEC Filings & Earnings Calls
EquiReason read 11 Insperity, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-07-30 — Insperity reported Q2 2026 results: revenue +2%, adjusted EBITDA +13%, but gross profit -3% and WSEEs -1% YoY..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.1B
- P/E TTM
- —
- Dividend yield
- 4.4%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
30 Jul 202610-QInsperity reported Q2 2026 results: revenue +2%, adjusted EBITDA +13%, but gross profit -3% and WSEEs -1% YoY.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.69B | +2% y/y |
| Gross Profit · Q2-2026 | $217M | -3% y/y |
| Net Income · Q2-2026 | $4M | +180% y/y |
| Adjusted EBITDA · Q2-2026 | $36M | +13% y/y |
| Adjusted EPS · Q2-2026 | $0.34 | +31% y/y |
| Diluted EPS · Q2-2026 | $0.10 | +171% y/y |
| Revenue per WSEE per month · Q2-2026 | $1838.00 | +3% y/y |
| Gross Profit per WSEE per month · Q2-2026 | $237.00 | -1% y/y |
Risks flagged
Healthcare cost inflation
“The cost of group health insurance and related employee benefits increased $25 per WSEE per month and increased 5.2% on a cost per covered employee basis in Q2 2026 as compared to Q2 2025.” · word for word
Workers' compensation cost spike
“Workers' compensation costs increased 35%, or $8 per WSEE per month, in Q2 2026 compared to Q2 2025 and has been impacted, in part, by elevated health care cost trends.” · word for word
Client attrition from pricing actions
“The number of WSEEs paid from new client sales and client retention decreased due in part to our margin recovery efforts” · word for word
29 Jul 20268-K · 2.02Average paid WSEEs 305,764 (-1% y/y); Revenue $1.70B (+2% y/y); Gross profit $217M (-3% y/y); Guidance: Full-year 2026 average WSEEs guided to 305,000-307,000 (YoY -1.0% to -1.6%); adjusted EPS $1.88-$2.43; adjusted EBITDA $185M-$225M.earningsopen
Figures in the filing · each found in the filing text
| Average paid WSEEs · Q2-2026 | 305,764 | -1% y/y |
| Revenue · Q2-2026 | $1.70B | +2% y/y |
| Gross profit · Q2-2026 | $217M | -3% y/y |
| Net income · Q2-2026 | $4M | +180% y/y |
| Adjusted EBITDA · Q2-2026 | $36M | +13% y/y |
| Diluted EPS · Q2-2026 | $0.10 | +171% y/y |
| Adjusted EPS · Q2-2026 | $0.34 | +31% y/y |
| Gross profit per WSEE · Q2-2026 | $237.00 | -1% y/y |
| Adjusted cash · Q2-2026 | $95M |
Guidance
Full-year 2026 average WSEEs guided to 305,000-307,000 (YoY -1.0% to -1.6%); adjusted EPS $1.88-$2.43; adjusted EBITDA $185M-$225M.
Guidance cut reflects continued decline in worksite employees, but margin recovery plan is on track with adjusted EBITDA expected to grow 41%-72% in 2026.
Risks flagged
Declining worksite employee count signals weak demand for HR outsourcing services, potentially due to macroeconomic headwinds or competitive pressures.
“Average paid WSEEs down 1% YoY in Q2 and full-year guidance implies further decline.”
Benefits cost inflation pressuring gross margins; benefits costs per covered employee up 5% YoY.
“Benefits costs per covered employee increased 5% over Q2 2025.” · word for word
High debt levels: $420 million outstanding under credit facility at June 30, 2026, with $50 million borrowed in Q2 for working capital.
“Outstanding borrowings of $420 million under credit facility at June 30, 2026.”
1 May 202610-QAverage WSEEs paid 303,049 (-1% y/y); Revenue $1.90B (+2% y/y); Gross profit $302M (-3% y/y)open
Figures in the filing · each found in the filing text
| Average WSEEs paid · Q1-2026 | 303,049 | -1% y/y |
| Revenue · Q1-2026 | $1.90B | +2% y/y |
| Gross profit · Q1-2026 | $302M | -3% y/y |
| Net income · Q1-2026 | $33M | -35% y/y |
| Adjusted EBITDA · Q1-2026 | $103M | +1% y/y |
| Adjusted EPS · Q1-2026 | $1.31 | -17% y/y |
| Gross profit per WSEE per month · Q1-2026 | $332.00 | -2% y/y |
| Middle market WSEEs as % of total · Middle Market · Q1-2026 | 29.0% |
Risks flagged
Healthcare cost inflation
“The cost of group health insurance and related employee benefits increased $28 per WSEE per month and increased 5.2% on a cost per covered employee basis in Q1 2026 as compared to Q1 2025.” · word for word
Workers' compensation cost increase
“Workers’ compensation costs increased 30%, or $7 per WSEE per month, in Q1 2026 compared to Q1 2025.” · word for word
Client attrition from margin recovery
“Average number of WSEEs paid per month decreased 1%, which was partially impacted by our margin recovery efforts.” · word for word
30 Apr 20268-K · 2.02Insperity Q1 2026 earnings: revenue +2% to $1.9B, net income $33M, adjusted EBITDA $103M, diluted EPS $0.88, adjusted EPS $1.31. Average WSEEs -1% to 303,049. Guidance updated: Q2 2026 adjusted EPS $0.02-$0.50, FY2026 adjusted EPS $1.60-$2.earningsopen
Figures in the filing · each found in the filing text
| Average WSEEs paid · Q1-2026 | 303,049 | -1% y/y |
| Revenue · Q1-2026 | $1.90B | +2% y/y |
| Net income · Q1-2026 | $33M | |
| Adjusted EBITDA · Q1-2026 | $103M | |
| Diluted EPS · Q1-2026 | $0.88 | |
| Adjusted EPS · Q1-2026 | $1.31 | |
| Gross profit · Q1-2026 | $302M | -3% y/y |
| Operating expenses · Q1-2026 | $240M | -1% y/y |
| Capital expenditures · Q1-2026 | $6M | |
| Adjusted cash · 2026-03-31 | $36M |
Guidance
Q2 2026: average WSEEs 302,500-304,500 (y/y -2.1% to -1.5%), adjusted EPS $0.02-$0.50 (y/y -92% to +92%), adjusted EBITDA $18M-$46M (y/y -44% to +44%). FY2026: average WSEEs 303,000-307,000 (y/y -2.3% to -1.0%), adjusted EPS $1.60-$2.60 (y/y +55% to +152%), adjusted EBITDA $170M-$230M (y/y +30% to +76%).
Guidance reflects continued WSEE decline but significant margin recovery; adjusted EPS and EBITDA expected to improve strongly in FY2026.
Risks flagged
Margin pressure from benefits cost inflation; benefits cost per covered employee +5%.
“Benefits costs per covered employee increased 5% over Q1 2025.” · word for word
Restructuring charges of $9 million related to workforce realignment.
“Operating expenses included $9 million in restructuring charges primarily related to severance.”
Outstanding borrowings of $370 million under credit facility.
“Outstanding borrowings of $370 million under our credit facility.” · word for word
14 Apr 2026DEF 14AProxy statement disclosing executive compensation, pay-for-performance metrics, and governance practices for 2025.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2025 | $131M | -52% y/y |
| Average Number of Worksite Employees Paid (WSEEs) · FY2025 | 0.9% | |
| Regular Annual Dividend per Share · FY2025 | $2.40 | 0% y/y |
| Net Income · FY2025 | $-7M | -108% y/y |
Risks flagged
Workday Partnership Execution Risk
“Most of the investment associated with these development efforts were reflected as expenses, resulting in adjusted EBITDA of $131 million, which is lower compared to the prior year.” · word for word
Insider Pledge Risk
“Mr. Sarvadi had 250,000 shares of our common stock pledged, which represented approximately 17.0% of the shares of our common stock Mr. Sarvadi beneficially owned.” · word for word
11 Feb 202610-KAverage WSEEs paid 310,089 (+1% y/y); Revenue $6.81B (+4% y/y); Gross Profit $900M (-14% y/y)open
Figures in the filing · each found in the filing text
| Average WSEEs paid · PEO HR Solutions · FY2025 | 310,089 | +1% y/y |
| Revenue · FY2025 | $6.81B | +4% y/y |
| Gross Profit · FY2025 | $900M | -14% y/y |
| Net Income (Loss) · FY2025 | $-7M | -108% y/y |
| Adjusted EBITDA · FY2025 | $131M | -51% y/y |
| Adjusted Net Income · FY2025 | $39M | -71% y/y |
| Diluted EPS · FY2025 | $-0.19 | -108% y/y |
| Adjusted EPS · FY2025 | $1.03 | -71% y/y |
| Client Retention · FY2025 | 83.0% | |
| Benefits Cost per Covered Employee · FY2025 | 9.2% |
Risks flagged
Healthcare Cost Inflation
“The cost of group health insurance and related employee benefits increased $61 per WSEE per month, or 9.2% on a cost per covered employee basis.” · word for word
Insufficient Pricing Power
“Gross profit per WSEE paid per month reflected, in part, a 3% pricing increase offset by a 6% increase in direct costs per WSEE.” · word for word
Profitability Deterioration
“Net income (loss) ... decreased 108% to $(7) million. Adjusted EBITDA decreased 51% to $131 million.”
Liquidity Tightening
“At December 31, 2025, we had working capital of $102 million compared to $155 million at December 31, 2024.” · word for word
10 Feb 20268-K · 2.02, 2.05Revenues $1.70B (+3% y/y); Average Paid WSEEs 312,377 (+1% y/y); Gross Profit $172M (-21% y/y); Guidance: Q1 2026 adjusted EPS $1.03-1.50; FY2026 adjusted EPS $1.69-2.72; adjusted EBITDA $170-230Mearningsopen
Figures in the filing · each found in the filing text
| Revenues · Q4-2025 | $1.70B | +3% y/y |
| Average Paid WSEEs · Q4-2025 | 312,377 | +1% y/y |
| Gross Profit · Q4-2025 | $172M | -21% y/y |
| Net Loss · Q4-2025 | $-33M | |
| Diluted EPS · Q4-2025 | $-0.88 | |
| Adjusted EBITDA · Q4-2025 | $-13M | |
| Adjusted EPS · Q4-2025 | $-0.60 | |
| Average Paid WSEEs (FY) · FY2025 | 310,089 | +1% y/y |
| Revenues (FY) · FY2025 | $6.80B | +4% y/y |
| Gross Profit (FY) · FY2025 | $900M | -14% y/y |
Guidance
Q1 2026 adjusted EPS $1.03-1.50; FY2026 adjusted EPS $1.69-2.72; adjusted EBITDA $170-230M
Guidance implies significant recovery in profitability from 2025 levels, but Q1 still weak.
Risks flagged
Elevated benefits costs (inpatient, outpatient, pharmacy, large claims) pressuring gross profit.
“elevated benefits costs were driven by inpatient, outpatient, and pharmacy trends, as well as frequency of large claim activity” · word for word
Restructuring plan with $9M charge; 4% reduction in non-sales positions.
“internal reorganization; elimination of approximately 4% of our non-sales positions; one-time charges of approximately $9 million”
16 Dec 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen
Risks flagged
Higher leverage covenant may indicate increased risk appetite or operational challenges
“Maximum leverage ratio increased from 3.00x to 3.75x.”
4 Nov 202510-QInsperity reported a sharp decline in profitability with net income swinging to a loss of $20M from a profit of $3M, driven by healthcare cost inflation.earningsopen
Figures in the filing · each found in the filing text
| Average WSEEs paid · Q3-2025 | 312,842 | +1% y/y |
| Revenues · Q3-2025 | $1.62B | +4% y/y |
| Gross profit · Q3-2025 | $195M | -15% y/y |
| Net income (loss) · Q3-2025 | $-20M | -767% y/y |
| Adjusted EBITDA · Q3-2025 | $10M | -74% y/y |
| Diluted EPS · Q3-2025 | $-0.53 | -857% y/y |
| Adjusted EPS · Q3-2025 | $-0.20 | -151% y/y |
| Gross profit per WSEE per month · Q3-2025 | $208.00 | -16% y/y |
| Revenues per WSEE per month · Q3-2025 | $1729.00 | +3% y/y |
| Operating cash flow · 9M-2025 | $-533M |
Risks flagged
Healthcare cost inflation
“The cost of group health insurance and related employee benefits increased $60 per WSEE per month and increased 9.1% on a cost per covered employee basis driven by elevated inpatient, outpatient and pharmacy trends and frequency of large claim activity in Q3 2025 as compared to Q3 2024.” · word for word
Workers' compensation cost increase
“Workers' compensation costs increased 15%, or $3 per WSEE per month, in Q3 2025 compared to Q3 2024.” · word for word
3 Nov 20258-K · 1.01, 2.02Revenue $1.60B (+4% y/y); Net loss $-20M; Adjusted EBITDA $10M; Guidance: Q4 adjusted EPS $(0.79)-$(0.16); full year adjusted EPS $0.84-$1.47open
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $1.60B | +4% y/y |
| Net loss · Q3-2025 | $-20M | |
| Adjusted EBITDA · Q3-2025 | $10M | |
| Diluted EPS · Q3-2025 | $-0.53 | |
| Average paid WSEEs · Q3-2025 | 312,842 | +1% y/y |
| Gross profit · Q3-2025 | $195M | -15% y/y |
| Operating expenses · Q3-2025 | $220M | -4% y/y |
| Share repurchases · First nine month | $19M |
Guidance
Q4 adjusted EPS $(0.79)-$(0.16); full year adjusted EPS $0.84-$1.47
Significant guidance cut due to healthcare cost pressure; new UHC contract expected to improve 2026 outlook.
Risks flagged
Elevated healthcare costs driven by inpatient, outpatient, and pharmacy trends; large claim frequency.
“Higher Q3 2025 healthcare costs were driven by elevated inpatient, outpatient and pharmacy trends and frequency of large claim activity.” · word for word
Q4 guidance implies significant year-over-year decline in profitability.
“Adjusted EPS $(0.79) — $(0.16)... Year-over-year decrease (77)% — (59)%” · word for word
Insperity, Inc. — questions
- What did Insperity, Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 10-Q on 2026-07-30 — Insperity reported Q2 2026 results: revenue +2%, adjusted EBITDA +13%, but gross profit -3% and WSEEs -1% YoY.
Every figure on this page comes from Insperity, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.